Organization (Industry)
Apyx Medical Corp
ClinicalTrials.gov lists Apyx Medical Corp as lead sponsor of 11 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Apyx Medical Corp: 11 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (4)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Cutis Laxa | 4 |
| Gynecomastia | 1 |
| Hypertrophy | 1 |
| Lymphocele | 1 |
Trials by start year as sponsor or collaborator (7)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2016 | 1 |
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 71% hit target (n=7) | 33% on time (n=9) |
Journals published in (17)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] | 4 |
| Lasers in surgery and medicine | 3 |
| Plastic and reconstructive surgery | 3 |
| Aesthetic plastic surgery | 2 |
| Archives of dermatology | 2 |
Showing 5 of 17 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 53 | 9 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 52,844,000 | -11,211,000 | 3,373,000 |
| 2024 | 48,102,000 | -23,463,000 | 5,080,000 |
| 2023 | 52,349,000 | -18,713,000 | 5,440,000 |
| 2022 | 44,510,000 | -23,184,000 | 4,544,000 |
| 2021 | 48,517,000 | -15,172,000 | 4,321,000 |
| 2020 | 27,711,000 | -11,896,000 | 3,920,000 |
| 2019 | 28,235,000 | -19,706,000 | 3,731,000 |
| 2018 | 16,605,000 | 62,719,000 | 2,549,000 |
| 2017 | 10,234,000 | -5,062,000 | 1,941,000 |
| 2016 | 8,819,000 | -11,550,000 | 1,033,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (15)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-12-01 | Follow-on offering | not disclosed | Edgar offerings |
| 2025-11-19 | Public offering | 9,400,000 | Sec extracted |
| 2025-11-18 | Other financing | not disclosed | Edgar offerings |
| 2025-11-17 | Other financing | not disclosed | Edgar offerings |
| 2024-11-08 | Other financing | not disclosed | Edgar offerings |
Showing 5 of 15 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 2 |
FDA recalls (15)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Velocity Disposable Bipolar Ablators - Product Usage: intended to be used for cutting, vaporization, and coagulation of soft tissue during arthroscopic surgical procedures. | Class II | 2021-02-01 |
| HNM Disposable Bipolar Ablators - Product Usage: intended to be used for cutting, vaporization, and coagulation of soft tissue during arthroscopic surgical procedures. | Class II | 2021-02-01 |
| ConMed Disposable Bipolar Ablators - Product Usage: intended to be used for cutting, vaporization, and coagulation of soft tissue during arthroscopic surgical procedures. | Class II | 2021-02-01 |
| Renuvion/ J-Plasma Precise Open Handpiece. Catalog numbers BVX-044-BPS, BVX-044-BPP, BVX-150-BPP, BVX-150-BPS, APYX-044-BPS, APYX-150-BPP, and APYX-150-BPS - Product Usage: for electrosurgical cutting, coagulation and ablation of soft tissue during open surgical procedures. | Class II | 2020-04-20 |
| Renuvion/ J-Plasma Precise Handpiece. Catalog numbers BVX-150B, BVX-270B, BVX-330B, BVX-270BPP, BVX- 330BPS, APYX-150B, APYX-270B, APYX-330B, APYX- 270BPP, and APYX-330BPS. Product Usage: for electrosurgical cutting, coagulation and ablation of soft tissue during open and laparoscopic surgical procedures. | Class II | 2020-04-20 |
Showing 5 of 15 recalls.
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Apyx Medical Corporation | Clearwater, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (96)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-01 | Follow-on offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-11-19 | Public offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-11-18 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 96 events.
Biomarker capability evidence (9)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| KLK3 | Trial sponsor | Named in trial inclusion criteria |
| LRP1 | Trial sponsor | Named in trial inclusion criteria |
| GLP1R | Trial sponsor | Named in trial exclusion criteria |
| PHLDA2 | Trial sponsor | Named in trial exclusion criteria |
| ELN | Trial sponsor | Mentioned in trial text |
Showing 5 of 9 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, fda warning letters, fda untitled letters, fda import refusals, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.